{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:27:16Z","timestamp":1791962836444,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To determine the association between the dexamethasone implant position in the vitreous cavity and ocular hypertension (OHT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective review of patients with at least one intravitreal dexamethasone implant injection between 2012 and 2016. Patients who had a minimum follow-up for 6 months and documented evidence of the implant position were included in the study. Steroid responders, glaucoma patients, vitrectomized eyes, and eyes with liquefied vitreous were excluded. Relevant data were collected from patient charts. Three positions (P1, P2, and P3) were identified: P1 (in contact with the pars plana\/ciliary body region), P2 (anterior to vortex veins), and P3 (posterior to vortex veins). Ocular hypertension was defined as absolute intraocular pressure &gt; 25 mmHg and\/or intraocular pressure rise &gt; 10 mmHg. The relationship between implant position and intraocular pressure rise after factoring in other characteristics was the outcome measure. Appropriate statistical analysis was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 377 patients (432 eyes; 257 males; 677 injections) were eligible for analysis. The median age was 57.24 (\u00b16.32) years. Eighty-eight eyes had OHT. Of these, 54 eyes had the implant in P1. P1 was associated with high intraocular pressure response (&gt;15 mmHg; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004) and early (&lt;15 days) onset OHT (r = 0.84, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Anterior position of dexamethasone implant in situ increases the risk of OHT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000001883","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T21:04:36Z","timestamp":1507669476000},"page":"2343-2349","source":"Crossref","is-referenced-by-count":19,"title":["INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION"],"prefix":"10.1097","volume":"38","author":[{"given":"Aditya","family":"Sudhalkar","sequence":"first","affiliation":[{"name":"Sudhalkar Eye Hospital and Retina Centre, Baroda, India;"},{"name":"Raghudeep Eye Hospital, Ahmedabad, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Croix-Rousse Teaching Hospital, Hospices Civil de Lyon, University of Lyon, Lyon, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[{"name":"L. V. Prasad Eye Institute, Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"Raghudeep Eye Hospital, Ahmedabad, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Vasavada","sequence":"additional","affiliation":[{"name":"Raghudeep Eye Hospital, Ahmedabad, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Ozurdex HURON Study Group: dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/eye.2016.205","article-title":"Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series","volume":"30","author":"Sudhalkar","year":"2016","journal-title":"Eye (Lond)"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00417-017-3660-7","article-title":"Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study","volume":"255","author":"Sudhalkar","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/IAE.0000000000001364","article-title":"Ocular hypertension after intravitreal dexamethasone (OZURDEX) sustained-release implant","volume":"37","author":"Chin","year":"2016","journal-title":"Retina"},{"key":"R7-20230816","first-page":"293","article-title":"Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease","volume":"48","author":"McLean","year":"1950","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1172\/JCI117943","article-title":"Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans","volume":"95","author":"Bamberger","year":"1995","journal-title":"J Clin Invest"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/archopht.1966.00970050034007","article-title":"The heritable nature of dexamethasone-induced ocular hypertension","volume":"75","author":"Armaly","year":"1966","journal-title":"Arch Ophthalmol"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archopht.1997.01100150377011","article-title":"Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids","volume":"115","author":"Johnson","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/02713688109019976","article-title":"Aqueous humour and plasma cortisol levels in glaucoma and cataract patients","volume":"1","author":"Rozsival","year":"1981","journal-title":"Curr Eye Res"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jfo.2015.03.002","article-title":"Ocular hypertension after intravitreal steroid injections: clinical update as of 2015","volume":"38","author":"Dot","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcles","year":"2017","journal-title":"Retina"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"626.e2","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archopht.1963.00960050502012","article-title":"Corticosteroids and intraocular pressure","volume":"70","author":"Becker","year":"1963","journal-title":"Arch Ophthalmol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids: a systematic review","volume":"58","author":"Kiddee","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1350-9462(98)00035-4","article-title":"Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma","volume":"18","author":"Wordinger","year":"1999","journal-title":"Prog Retin Eye Res"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archopht.123.1.129-b","article-title":"Anterior chamber transit of triamcinolone after intravitreal injection","volume":"123","author":"Ruiz-Moreno","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2004.03.001","article-title":"Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection","volume":"138","author":"Singh","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Ozurdex MEAD study group intraocular pressure in patients with diabetic macular edema TREATED with dexamethasone intravitreal implant in the 3-year MEAD study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/IAE.0000000000001234","article-title":"Real-life study in diabetic macular edema TREATED with dexamethasone implant: the Reldex study","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/IAE.0000000000001114","article-title":"Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or OPEN-ANGLE glaucoma","volume":"37","author":"Vi\u00e9","year":"2017","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201812000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:07:26Z","timestamp":1692230846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201812000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001883","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}